Prior to co-founding Medicxi, Michèle was a partner at Index Ventures for 10 years, having joined the firm in 2006. During that time she invested and continues to serve on the boards of a number of Index Life Sciences portfolio companies including Epsilon 3 Bio, Linguaflex and Human Antibody Factory. She also sits on the boards of Palladio Biosciences, Gadeta and Diasome Pharmaceuticals, one of the first investments of the new Medicxi Growth fund. She was also a Director at OncoEthix (Sold to Merck Pharmaceuticals) and Aegerion (NASDAQ: AEGR).
Prior to joining Index, Michèle was Investment Director at Edmond de Rothschild Investment Partners in Paris for 3 years, where she served on the board of U3 Pharma. Before that, she spent more than 15 years in several development and marketing positions at Sanofi International, BMS, RPR/ Gencell/ Aventis International and Serono International.
She currently serves on the board of directors of Ipsen Pharmaceuticals (Euronext:IPN). She also sits on the investment committees of the accelerator and technology transfer companies of Paris-Saclay and France-Nord.
Michèle completed her medical studies in France at Paris Ouest University.